Cingulate Inc. Pre-Tax Income
Cingulate Inc. (CING) reported Pre-Tax Income of -$5.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-13
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$5.87M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$9.31M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$6.27M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$7.34M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$22.45M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$16.56M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$23.53M.
- Cingulate Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$17.68M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.87M 10-Q · filed 2026-08-13 | -$15.18M 10-Q · filed 2026-08-13 | -$21.46M derived: sum of 3 quarters · filed 2026-08-13 | -$28.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$9.31M 10-Q · filed 2026-05-14 | -$15.58M derived: sum of 2 quarters · filed 2026-05-14 | -$22.93M derived: sum of 3 quarters · filed 2026-05-14 | -$27.91M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$13.61M derived: sum of 2 quarters · filed 2026-03-18 | -$18.60M derived: sum of 3 quarters · filed 2026-08-13 | -$22.45M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | -$7.34M 10-Q · filed 2025-11-13 | -$12.32M derived: sum of 2 quarters · filed 2026-08-13 | -$16.18M 10-Q · filed 2025-11-13 | -$22.41M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$4.98M 10-Q · filed 2026-08-13 | -$4.79M 10-Q · filed 2025-08-19 | -$8.84M 10-Q · filed 2026-08-13 | -$8.59M 10-Q · filed 2025-08-19 | -$15.07M derived: sum of 3 quarters · filed 2026-08-13 | -$19.19M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$3.85M 10-Q · filed 2026-05-14 | -$3.80M 10-Q · filed 2025-05-08 | -$10.08M derived: sum of 2 quarters · filed 2026-05-14 | -$14.21M derived: sum of 3 quarters · filed 2026-05-14 | -$17.42M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$10.36M derived: sum of 2 quarters · filed 2026-03-18 | -$13.57M derived: sum of 3 quarters · filed 2026-03-18 | -$16.56M 10-K · filed 2026-03-18 | -$15.55M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$4.13M 10-Q · filed 2025-11-13 | -$3.23M 10-Q · filed 2024-11-07 | -$7.34M derived: sum of 2 quarters · filed 2025-11-13 | -$10.33M 10-Q · filed 2025-11-13 | -$9.41M 10-Q · filed 2024-11-07 | -$17.24M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$3.21M 10-Q · filed 2025-08-19 | -$6.18M 10-Q · filed 2025-08-19 | -$13.12M derived: sum of 3 quarters · filed 2025-08-19 | -$19.10M derived: sum of 4 quarters · filed 2025-08-19 | ||||
| 2024-03-31 | -$2.97M 10-Q · filed 2025-05-08 | -$9.91M derived: sum of 2 quarters · filed 2025-05-08 | -$15.89M derived: sum of 3 quarters · filed 2025-05-08 | -$22.50M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$12.91M derived: sum of 2 quarters · filed 2025-03-27 | -$19.53M derived: sum of 3 quarters · filed 2025-03-27 | -$23.53M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$5.98M 10-Q · filed 2024-11-07 | -$12.60M derived: sum of 2 quarters · filed 2024-11-07 | -$16.60M 10-Q · filed 2024-11-07 | -$21.21M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$6.62M 10-Q · filed 2024-08-13 | -$10.62M 10-Q · filed 2024-08-13 | -$15.23M derived: sum of 3 quarters · filed 2024-08-13 | -$19.25M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$4.00M 10-Q · filed 2024-05-08 | -$8.61M derived: sum of 2 quarters · filed 2024-05-08 | -$12.64M derived: sum of 3 quarters · filed 2024-05-08 | -$16.68M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | -$4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$8.63M derived: sum of 2 quarters · filed 2024-04-01 | -$12.67M derived: sum of 3 quarters · filed 2024-04-01 | -$17.68M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$4.03M 10-Q · filed 2023-11-13 | -$8.07M derived: sum of 2 quarters · filed 2023-11-13 | -$13.07M 10-Q · filed 2023-11-13 | -$15.72M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$4.04M 10-Q · filed 2023-08-14 | -$9.04M 10-Q · filed 2023-08-14 | -$11.70M derived: sum of 3 quarters · filed 2023-08-14 | -$26.99M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$5.00M 10-Q · filed 2023-05-10 | -$7.66M derived: sum of 2 quarters · filed 2023-05-10 | -$22.95M derived: sum of 3 quarters · filed 2023-05-10 | -$24.38M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$17.94M derived: sum of 2 quarters · filed 2023-03-10 | -$19.38M derived: sum of 3 quarters · filed 2023-03-10 | -$20.71M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | -$15.29M 10-Q · filed 2022-11-14 | -$16.72M derived: sum of 2 quarters · filed 2022-11-14 | -$18.06M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$1.43M 10-Q · filed 2022-08-11 | -$2.77M 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | -$1.33M 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | -$7.18M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |